Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression.

Curr Oncol · 2023 · PMC10453050 · PMID 37623024

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although this did not reach statistical significance, it could have contributed to the improved outcomes of the PD-L1 ≥ 1% subgroup on durvalumab.

also in 111,027 other papers

a positive trendno p-value reported

Within the PD-L1 ≥ 1% subgroup, the increase in OS was statistically significant in the PD-L1 ≥ 50% of patients, but there was only a positive trend in the PD-L1 1–49% of patients ( Figure S1 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.